Functional characterization of novel germline TP53 variants in Swedish families

被引:10
|
作者
Kharaziha, Pedram [1 ]
Ceder, Sophia [1 ]
Axell, Olga [1 ]
Krall, Moritz [1 ]
Fotouhi, Omid [1 ]
Bohm, Stefanie [1 ]
Lain, Sonia [2 ]
Borg, Ake [3 ]
Larsson, Catharina [1 ]
Wiman, Klas G. [1 ]
Tham, Emma [4 ,5 ]
Bajalica-Lagercrantz, Svetlana [1 ,5 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, BioClinicum J6-20, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden
[3] Lund Univ, Div Oncol Pathol, Lund, Sweden
[4] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[5] Karolinska Univ Hosp, Dept Clin Genet, Stockholm, Sweden
关键词
germline TP53 mutation; hereditary breast cancer; Li-Fraumeni syndrome; p53; activity; LI-FRAUMENI SYNDROME; ONSET BREAST-CANCER; MUTANT P53; MUTATION CARRIERS; IMAGING SURVEILLANCE; RISK; BINDING; BRCA2;
D O I
10.1111/cge.13564
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Pathogenic germline TP53 variants predispose to a wide range of early onset cancers, often recognized as the Li-Fraumeni syndrome (LFS). They are also identified in 1% of families with hereditary breast cancer (HrBC) that do not fulfill the criteria for LFS. In this study, we present a total of 24 different TP53 variants identified in 31 Swedish families with LFS or HrBC. Ten of these variants, nine exonic and one splice, have previously not been described as germline pathogenic variants. The nine exonic variants were functionally characterized and demonstrated partial transactivation activity compared to wild-type p53. Some show nuclear localization similar to wild-type p53 while others possess cytoplasmic or perinuclear localization. The four frameshift variants (W91Gfs*32, L111 Wfs*12, S227 Lfs*20 and S240Kfs*25) had negligible, while F134 L and T231del had low level of p53 activity. The L111 Wfs*12 and T231del variants are also deficient for induction of apoptosis. The missense variant R110C retain p53 effects and the nonsense E349* shows at least partial transcription factor activity but has reduced ability to trigger apoptosis. This is the first functional characterization of novel germline TP53 pathogenic or likely pathogenic variants in the Swedish cohort as an attempt to understand its association with LFS and HrBC, respectively.
引用
收藏
页码:216 / 225
页数:10
相关论文
共 50 条
  • [21] Sarcomas in TP53 Germline Mutation Carriers A Review of the IARC TP53 Database
    Ognjanovic, Simona
    Olivier, Magali
    Bergemann, Tracy L.
    Hainaut, Pierre
    CANCER, 2012, 118 (05) : 1387 - 1396
  • [22] Clinical management of TP53 mosaic variants found on germline genetic testing
    Ward, Abigail
    Farengo-Clark, Dana
    Mckenna, Danielle B.
    Safonov, Anton
    Good, Madeline
    Le, Anh
    Kessler, Lisa
    Shah, Payal D.
    Bradbury, Angela R.
    Domchek, Susan M.
    Nathanson, Katherine L.
    Powers, Jacquelyn
    Maxwell, Kara N.
    CANCER GENETICS, 2024, 284 : 43 - 47
  • [23] Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants
    Fortuno, Cristina
    Lee, Kristy
    Olivier, Magali
    Pesaran, Tina
    Mai, Phuong L.
    de Andrade, Kelvin C.
    Attardi, Laura D.
    Crowley, Stephanie
    Evans, D. Gareth
    Feng, Bing-Jian
    Foreman, Ann K. M.
    Frone, Megan N.
    Huether, Robert
    James, Paul A.
    McGoldrick, Kelly
    Mester, Jessica
    Seifert, Bryce A.
    Slavin, Thomas P.
    Witkowski, Leora
    Zhang, Liying
    Plon, Sharon E.
    Spurdle, Amanda B.
    Savage, Sharon A.
    HUMAN MUTATION, 2021, 42 (03) : 223 - 236
  • [24] Development of a rapid functional assay on peripheral blood for clinical interpretation of germline TP53 variants and detection of non-coding functional variants
    Raad, S.
    Rolain, M.
    Coutant, S.
    Derambure, C.
    Lanos, R.
    Charbonnier, F.
    Bou, J.
    Bouvignies, E.
    Lienard, G.
    Vasseur, S.
    Farrel, M.
    Ingster, O.
    Baert-Desurmont, S.
    Kasper, E.
    Bougeard, G.
    Frebourg, T.
    Tournier, I.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 91 - 91
  • [25] The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants
    Lazarian, Gregory
    Theves, Floriane
    Hormi, Myriam
    Eclache, Virginie
    Poulain, Stephanie
    Bidet, Audrey
    Pastoret, Cedric
    Veronese, Lauren
    Delabesse, Eric
    Estienne, Marie-Helene
    Nadal, Nathalie
    Davi, Frederic
    Nguyen-Khac, Florence
    Lode, Laurence
    Sujobert, Pierre
    Naguib, Dina
    Raynaud, Sophie
    Giraudier, Stephane
    Kosmider, Olivier
    Etancelin, Pascaline
    Cornillet-Lefebvre, Pascale
    Miguet, Laurent
    Leblond, Veronique
    Letestu, Remi
    Soussi, Thierry
    Cymbalista, Florence
    Baran-Marszak, Fanny
    BLOOD, 2019, 134
  • [26] Three germline mutations in the TP53 gene
    Cornelis, RS
    vanVliet, M
    vandeVijver, MJ
    Vasen, HFA
    Voute, PA
    Top, B
    Khan, PM
    Devilee, P
    Cornelisse, CJ
    HUMAN MUTATION, 1997, 9 (02) : 157 - 163
  • [27] Sarcomas in TP53 germline mutation carriers
    Ognjanovic, Simona
    Olivier, Magali
    Bergemann, Tracy L.
    Hainaut, Pierre
    CANCER RESEARCH, 2011, 71
  • [28] Childhood adrenocortical carcinoma as a sentinel cancer for detecting families with germline TP53 mutations
    Choong, S. S.
    Latiff, Z. A.
    Mohamed, M.
    Lim, L. L. W.
    Chen, K. S.
    Vengidasan, L.
    Razali, H.
    Rahman, E. J. Abdul
    Ariffin, H.
    CLINICAL GENETICS, 2012, 82 (06) : 564 - 568
  • [29] Pathogenic germline variants of TP53 gene are rare in patients with chronic lymphocytic leukemia
    Pavlova, Sarka
    Malcikova, Jitka
    Gombikova, Johana
    Smardova, Jana
    Plevova, Karla
    Kotaskova, Jana
    Dvorackova, Barbara
    Vonkova, Barbara Kunt
    Zavacka, Kristyna
    Navrkalova, Veronika
    Trizuljak, Jakub
    Doubek, Michael
    Pospisilova, Sarka
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 542 - 543
  • [30] TP53 pathogenic variants with low allele fraction in germline genetic testing.
    Wu, Yanqing
    Fan, Wenzhe
    Xue, Miao
    Tang, Yiyang
    Peisu, Suo
    Yang, Bo
    Huang, Tanxiao
    Zhang, Jing
    Li, Jiaping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)